New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
08:03 EDTABBV, OSUROraSure announces new co-promotion agreement with AbbVie
OraSure Technologies announced that it has entered into a Master Program Services and Co-Promotion Agreement with AbbVie (ABBV) under which AbbVie and OraSure will co-promote the Company's OraQuick HCV Rapid Test in the U.S. The product will be used to test individuals at-risk for hepatitis C. OraSure will be responsible for manufacturing and selling the product directly into all markets. Under the agreement, OraSure has granted exclusive promotion rights to AbbVie for the OraQuick HCV test in certain markets and will provide certain additional services in support of HCV testing. In exchange for the exclusive rights granted to AbbVie, OraSure will receive up to $75M in exclusivity payments over the term of the agreement, which runs through December 31, 2019. In addition, upon achievement of certain performance-based milestones, OraSure will be eligible to receive additional payments annually over the life of the agreement.
News For OSUR;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
11:39 EDTABBVBass denied request for review of Biogen multiple sclerosis drug patent
Subscribe for More Information
September 1, 2015
07:31 EDTABBVBristol-Myers, AbbVie say FDA accepts BLA for Empliciti for priority review
Subscribe for More Information
August 31, 2015
14:00 EDTABBVAbbVie September calls active
AbbVie September 65 and 67.5 calls are active on total call volume of 37K contracts (9K puts). September weekly call option implied volatility is at 37, September is at 36, October is at 31; compared to its 52-week range of 18 to 36. Active call volume suggests traders taking positions for price movement.
August 25, 2015
19:34 EDTABBVExperts tell White House to expand use of Hepatitis C drugs, NYT says
Health care experts from the Public Health Service and the Advisory Council on H.I.V./AIDS have recommended that Medicaid officials expand the use of costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni, reports the New York Times, citing correspondence sent to the White House. The advisory council said current usage limitations on the drugs are "unreasonable," but it also suggested that manufacturers disclose drug development costs in the face of the significant price tags on modern Hepatitis C treatments. Reference Link
09:03 EDTABBVAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use